(No abstract allowed for commentary).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000529972 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Differential Cardiotoxicity of Ibrutinib Versus Chemoimmunotherapy in Chronic Lymphocytic Leukemia: A Population-Based Study.
J Clin Med
December 2024
Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool L7 8YA, UK.
Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia among adults, particularly in Western nations. The introduction of Bruton's tyrosine kinase (BTK) inhibitors as a treatment of CLL, namely, ibrutinib, which is a first-generation BTK inhibitor, has significantly improved the treatment landscape for CLL. However, ibrutinib has been associated with an increased risk of atrial fibrillation (AF) and hypertension.
View Article and Find Full Text PDFEpidemiology, clinical characteristics and potential mechanism of ibrutinib-induced ventricular arrhythmias.
Front Pharmacol
November 2024
Department of Cardiology, China-Japan Union Hospital of Jilin University, Jilin Provincial Cardiovascular Research Institute, Changchun, China.
Article Synopsis
- Ibrutinib, a drug commonly used for B-cell lymphoma, has shown great effectiveness but is linked to serious heart issues like atrial fibrillation and ventricular arrhythmias, raising concerns in both cardio-oncology and hematology.
- While atrial fibrillation caused by ibritunib is well understood, the mechanisms behind ventricular arrhythmias are still being researched, leading to variability in their reported incidence due to factors like under-recognition.
- The article aims to provide a thorough overview of the epidemiology, mechanisms, and clinical implications of ibritunib-induced ventricular arrhythmias, suggesting management strategies for patients on this treatment.
Mitigating ibrutinib-induced ventricular arrhythmia and cardiac dysfunction with metformin.
Cancer Innov
February 2025
Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Second Hospital of Tianjin Medical University Tianjin China.
Background: Ibrutinib is a first-line drug that targets Bruton's tyrosine kinase for the treatment of B cell cancer. However, cardiotoxicity induced by ibrutinib is a major side effect that limits its clinical use. This study aimed to investigate the mechanism of ibrutinib-induced cardiotoxicity and evaluate the protective role of metformin.
View Article and Find Full Text PDFAtrial fibrillation burden and clinical outcomes following BTK inhibitor initiation.
Leukemia
October 2024
Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, OH, USA.
Article Synopsis
- BTK inhibitors are effective for treating B-cell malignancies but are linked to heart issues like atrial fibrillation (AF), the extent and seriousness of which were previously unknown.
- A study monitored B-cell cancer patients on BTK inhibitors from 2009-2020, revealing that 72.4% developed arrhythmias, with 16.3% experiencing new cases of AF and 14.3% showing high AF burden.
- Higher AF burden was correlated with increased risk of major cardiac events and mortality, highlighting the need for careful monitoring and management in patients treated with BTK inhibitors.
Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis.
Ann Hematol
November 2024
Department of Hematology and Bone Marrow Transplant, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.
Bruton tyrosine kinase (BTK) inhibitors play an important role in targeted treatment of B-cell lymphoproliferative disorders. However, adverse events may limit the proper course of treatment in many patients. The purpose of this study is to compare the risk of cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia (CLL) or small cell lymphocytic lymphoma (SLL) treated with the first-generation BTK inhibitor ibrutinib versus second-generation acalabrutinib, using real-world data from a collaborative multinational network.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!